Earnings History Data for Zynerba Pharmaceuticals (ZYNE) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-08-2023	PM		ZYNE	Zynerba Pharmaceuticals	18.00	-0.21	-0.20	0.00		1.32	0.99 (290.86%)	0.0	0.0 (0.00%)	0.25 - 1.38	18,846,130	100,000	0
Zynerba surges on $200M buyout deal with Harmony Biosciences [8/14/2023 10:17 AM]
14-11-2022	PM		ZYNE	Zynerba Pharmaceuticals	29.00	-0.20	-0.21	0.00	Zynerba Pharmaceuticals GAAP EPS of -$0.20 beats by $0.03 [11/14/2022 8:39 AM]	0.63	-0.02 (-3.08%)	0.67	0.02 (3.08%)	0.61 - 4.36	340,352	200,000	1,799
Zynerba Pharmaceuticals GAAP EPS of -$0.20 beats by $0.03 [11/14/2022 8:39 AM] Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights [Nov-14-22 07:30AM]
10-08-2022	PM		ZYNE	Zynerba Pharmaceuticals	54.00	-0.24	-0.21	0.00	Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01 [8/10/2022 7:48 AM]	1.26	0.06 (5.10%)	1.24	0.04 (3.33%)	0.84 - 4.67	692,154	410,000	5,664
Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01 [8/10/2022 7:48 AM]
16-05-2022	PM	6:00 AM ET (May 16)	ZYNE	Zynerba Pharmaceuticals	39.00	-0.21	-0.22	0.00		0.9298	0.07 (8.66%)	0.87	0.01 (1.67%)	0.84 - 6.07	395,253	330,000	4,013
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights [May-16-22 07:00AM]
01-03-2022	PM		ZYNE	Zynerba Pharmaceuticals	95.00	-0.22	-0.27	0.00	Zynerba Pharmaceuticals GAAP EPS of -$0.22 beats by $0.04 [3/1/2022 6:13 AM]	2.13	-0.12 (-5.53%)	2.27	0.01 (0.44%)	2.13 - 7.03	362,277	340,000	9,981
Zynerba Pharmaceuticals GAAP EPS of -$0.22 beats by $0.04 [3/1/2022 6:13 AM] Zynerba Pharma gets orphan drug designation from European Commission for Zygel in FXS [2/28/2022 5:26 PM] Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights [Mar-01-22 06:00AM] Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel in Fragile X Syndrome [Feb-28-22 04:05PM] Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22q11.2 Deletion Syndrome [Feb-28-22 07:00AM]
12-05-2021	PM		ZYNE	Zynerba Pharmaceuticals, Inc.	172.00	-0.20	-0.24	0.00	Zynerba Pharmaceuticals EPS beats by $0.05 [5/12/2021 6:55 AM]	4.24	0.08 (1.92%)	4.30	0.14 (3.37%)	3.12 - 9.00	2,790,264	1,530,000	10,936
Zynerba Pharmaceuticals EPS beats by $0.05 [5/12/2021 6:55 AM] Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights [May-12-21 06:45AM]
10-03-2021	PM		ZYNE	Zynerba Pharmaceuticals, Inc.	122.17	-0.33	-0.38	-0.46	Zynerba Pharmaceuticals EPS in-line [3/10/2021 7:01 AM]	4.34	-0.20 (-4.43%)	4.64	0.10 (2.20%)	2.55 - 9.00	1,487,990	2,191,756	37,907
Zynerba Pharmaceuticals EPS in-line [3/10/2021 7:01 AM] Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights [Mar-10-21 06:45AM]
10-08-2020	PM		ZYNE	Zynerba Pharmaceuticals, Inc.	105.29	-0.78	-0.46	-0.50	Zynerba Pharmaceuticals EPS misses by $0.33 [8/10/2020 6:54 AM]	3.84	-0.23 (-5.65%)	4.05	-0.02 (-0.49%)	2.55 - 12.51	564,234	628,388	2,400